Business Context and Reporting Period
Company: MedaSorb Technologies Corporation (operating subsidiary: CytoSorbents, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Stage: Development Stage (Pre-revenue)
Core Technology: Hemoperfusion devices (CytoSorb™ and BetaSorb™) utilizing proprietary adsorbent polymer technology to remove middle molecular weight toxins (cytokines) from blood.
The Company is focused on commercializing CytoSorb™ for the adjunctive treatment of sepsis. It is currently conducting a pivotal randomized clinical trial in Germany to support a CE Mark application in Europe, anticipating approval in the first half of 2010 if the study is successful. The Company has no commercial operations and has not generated revenue to date.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,017,890) | $(3,350,754) |
| Accumulated Deficit | $(75,461,481) | $(71,538,209) |
| Research & Development Expenses | $1,983,483 | $1,415,509 |
| Cash and Cash Equivalents (Dec 31) | $2,749,208 | $211,613 |
| Current Liabilities | $977,704 | $906,868 |
| Net Cash Used in Operating Activities | $(2,365,349) | $(2,627,839) |
Liquidity: As of December 31, 2008, the Company held approximately $2.75 million in cash, primarily resulting from a $5.29 million private placement of Series B Preferred Stock in June and August 2008. Management believes this is sufficient to fund operations through the third quarter of 2009.
Material Changes vs. Prior Period
- Cash Position: Cash increased significantly from $211,613 in 2007 to $2,749,208 in 2008 due to the Series B financing.
- Operating Loss: Net loss decreased slightly by approximately $333,000 year-over-year, driven by a reduction in General and Administrative expenses, partially offset by an increase in R&D costs.
- Capital Structure: Issued Series B Preferred Stock (10% cumulative convertible) in 2008. Series A Preferred Stock dividends were paid in additional shares of preferred stock rather than cash.
- Clinical Progress: Expanded the German clinical trial for CytoSorb™ from 7 to 10 hospital sites (as of March 2009) and enrolled 22 patients by the end of the reporting period.
Outlook, Risks, and Management Commentary
Guidance and Outlook:
- Regulatory Path: Targeting CE Mark approval in Europe for CytoSorb™ in the first half of 2010, contingent on successful clinical trial results and adequate funding.
- Commercialization: No revenue is expected until regulatory approval is obtained. The Company plans to launch sales in Europe (Germany, France, Italy, Spain, UK) via local distributors.
- Funding Needs: The Company will require additional financing after the third quarter of 2009 to complete clinical studies and commercialization.
Material Risks:
- Going Concern: The independent auditor has expressed substantial doubt about the Company's ability to continue as a going concern due to recurring losses and negative cash flows.
- Regulatory Uncertainty: No assurance that CytoSorb™ will obtain CE Mark or FDA approval, or that clinical data will be viewed as sufficient by the medical community.
- Capital Requirements: Failure to raise additional capital could force the suspension of R&D or cessation of operations.
- Intellectual Property: Potential disputes regarding patent ownership (e.g., Dow Chemical patents) and ongoing royalty obligations to Purolite (2.5% to 5% on future sales).
Unusual Items:
- Preferred Stock Penalties: The Company incurred penalties in 2007 related to the non-registration of Series A Preferred Stock, which were settled via the issuance of additional shares.
- Stock-Based Compensation: Significant non-cash expenses related to stock options and warrants issued to employees, consultants, and investors.
Investor Verification Checklist
- Cash Runway: Verify the Company's ability to secure financing before the third quarter of 2009 to avoid operational suspension.
- Clinical Trial Enrollment: Monitor the pace of patient enrollment in the German sepsis trial (target: 80-100 patients) and the timeline for data readout.
- Preferred Stock Terms: Review the conversion prices and dividend rates of Series A and Series B Preferred Stock, noting the potential for significant dilution upon conversion.
- Regulatory Milestones: Track the submission and approval status of the CE Mark application with the European Notified Body.
- Intellectual Property Status: Confirm the status of patent litigation risks, specifically regarding Dow Chemical and Purolite agreements.